West Pharmaceutical Services' financial status and prospects are in the limelight with their participation in an upcoming investor conference. Performance-wise, however, West Pharmaceuticals has seen some underperformance when compared to its competitors. Nevertheless, with various firm taking positions, such as Kornitzer Capital Management Inc. KS and Fiera Capital Corp, this incites the potential for future growth. West Pharmaceutical Services have seen a good amount of Price volatility, with fluctuations becoming more common due to earnings misses and beats, as well as forecast adjustments. The company's growth drivers are still deemed attractive, suggesting potential long term holding benefit.
Their dividend declarations have earned them recognition as Dividend Aristocrats. Lastly, despite the company missing earnings expectations, analysts have adjusted their forecasts suggesting a belief in the company's potential for recovery. The company made a noteworthy announcement with the introduction of Daikyo Crystal Zenith® (CZ) Ready-to-Use Nested Vials in Tub at the International Society of Cell and Gene Therapy. Despite lower demand forecasts, West Pharmaceutical Services' financials remain strong.
West Pharmaceutical Services WST News Analytics from Wed, 27 Jun 2018 06:43:43 GMT to Fri, 06 Sep 2024 23:06:04 GMT - Rating 3 - Innovation 4 - Information 7 - Rumor -4
